Patritumab Deruxtecan (U3-1402)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Patritumab Deruxtecan (U3-1402), covering 2025-12-22 to 2025-12-23. Get the full timeline:
Most recent: Clinical Trial Update: Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer [Phase 2]